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     Cancer stem cells are the new targets of the “war on cancer” (Lenz 2008; for the 
“war on cancer” see the US National Cancer Act signed by President Richard Nixon). 
After 40 years and the 105 billion dollars spent by the National Cancer Institute alone, 
improvement has been low (less than 5%), cancers are still there, killing thousands of 
people every days, while other important causes of death like stroke and cardiovascular 
diseases have substantially declined (improving by more than 64%) (numbers from 
Kolata 2009; see also the well-known Facts & Figures of the American Cancer Society). 
Despite undeniable progress, the comparative failure of oncology has put the whole 
therapeutic classical enterprise under suspicion. This context clearly opened a window 
for proposed original therapeutic strategies that would give hope of “breaking the 
cancer war stalemate” (Haber et al. 2011, p.19). Thus, when the role and existence of 
the so called cancer stem cells have been brought on the table with the proposition 
of an entirely new and very heuristic therapeutic strategy against cancers, it didn’t 
take long to spread. Cancer stem cells (CSCs) are cancerous cells with stemness 
properties. According to the cancer stem cell model of carcinogenesis, which is based 
on accumulating evidence, the CSCs are the only tumorigenic cells of the cancers. This 
means that cancers are initiated, developed and spread by the CSCs and never by any 
other cancerous cells. From this model of carcinogenesis, biologists have deduced (1) 
that relapses after apparently successful therapies are due to resistance of few CSCs and 
(2) that it would be necessary and sufficient to kill those CSC in order to cure cancer.
     In this chapter, we are going to question this therapeutic strategy and show that it 
relies on historico-ontological choices, which remain to be supported. For this purpose 
we are first going to depict the coming into being of the cancer stem cell theory. We 
are then going to highlight the ontological perspective that has been raised by the CSC 
biographies. Other stem cells biographies have raised other competing ontological 
Stemness ontology and therapeutic strategies 78
perspectives on stemness. This state of competition will lead us to analyze the 
consequences of those distinct ontologies of stemness on the CSC targeting strategy.
Cancer stem cells biographies
     Cancer biology is highly complex. It gathers together heterogeneous diseases 
affecting various parts of the organism at diverse levels of organization (genetic and 
epigenetic, molecular and cellular) and involving a multitude of genes and molecular 
pathways. This complexity is argued to explain why a cure is still lacking: brain 
cancers are very distinct from blood cancers, among which acute myeloid leukemia are 
different from chronic lymphoid leukemia, which themselves can result from various 
deregulations of normal functions. There is thus very little hope to find a universal cure.
     The classical therapeutics, surgery apart, involve anti-mitotic agents. They destroy 
cells in proliferation (which result in various side effects like hair loss, digestive 
disorders and blood aplasia). This therapeutic strategy came from the common apparent 
problem of proliferation involved in every cancer. Indeed, cancers cells are assumed 
to escape the steady state of the organism and outgrow. Thus, cancer cells have been 
thought to divide a lot. But this has been proven wrong since the 50’s: cell division is 
equivalent in cancers and in steady-state tissues. A lot of cancer cells are not dividing 
(Astaldi et al. 1947; Astaldi and Mauri 1950; Killmann et al 1963; Mauer & Fisher 
1966). This observation has been explained by two concurrent hypotheses: either all 
cancer cells have the ability to divide but do so at different stochastic rates, or most 
cancer cells do not divide but there is a pool of stem cells that feed the cancer cells 
population. Those two explanations have been called respectively “self-maintaining 
system hypothesis” and “stem cells hypothesis” (Clarkson 1969; Clarkson et al. 1970; 
Gavosto et al 1967a and 1967b). For leukemias, the latter hypothesis has gained support 
from clonogenic studies. Those deserve historical emphasis.
Leukemic and hematopoietic stem cells
     The nuclear area led to fear of major radiations (which could be caused by nuclear 
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wars, by fallout from nuclear weapon testing or by production accidents –all these cases 
had occurred). The first cause of death after non-directly lethal radiations was blood 
depletion. Thus biologists began to actively search a way to rescue the hematopoietic 
system by transplantations of bone marrow cells (Lorenz et al. 1951; Kraft 2009). These 
led to the constitution of in vitro and in vivo assays which allow studying the capacity of 
a single cell to produce an entire population of cells, called a “clone” (Till & McCulloch 
1961; Becker et al. 1963). Using these assays, biologists have highlighted the existence 
of a hierarchy of cells with distinct clonogenic abilities in both normal blood system 
and leukemias (Till & McCulloch 1980; Metcalf et al. 1969; McCulloch 1983; Griffin 
& Löwenberg 1986). At the top of the hierarchy are the so-called “hematopoietic stem 
cells” and “leukemic stem cells” respectively. These cells are highly able to produce 
clones containing different kind of cells. But it rapidly appeared that the most immature 
cells detectable by these assays weren’t the true hematopoietic and leukemic stem cells 
(Dick 2008; Griffin & Löwenberg 1986; Buick et al. 1979; McCulloch & Till 1981).
     In the 90’s, the new hopes raised by gene therapies to cure blood genetic diseases 
caused by single-gene defects urged the identification of hematopoietic stem cells. 
Indeed, the aim of gene therapies is the “permanent correction of genetic deficiencies of 
the hematopoietic system” (Larochelle et al. 1995, p. 163). This necessitates transducing 
the right target, which is the hematopoietic stem cell. Otherwise the disease is likely to 
reappear (Larochelle 1996). The development of three technologies played a major role 
in this race to the identification of hematopoietic stem cells: production of strains of 
immunodeficient mice in which xenotransplantation of human cells was possible, FACS 
technologies (Fluorescence-Activated Cell Sorting), and production of monoclonal 
antibodies. The latter two, once combined, allow cell sorting according to their cell 
surface antigens. Immunodeficient mice were highly needed for modeling and studying 
blood cancers, HIV, and immune disorders (see Schults et al. 2007; Belizário 2009). A 
lot of strains were rapidly produced among which the NOD-SCID mice (Non Obese 
Diabetic- Severe Combined Immunodeficiency) played a major role in the identification 
of human hematopoietic and leukemic stem cells (Dick 1996).
     The coming into being of the FACS technology was also very exciting. This 
ingenious technology was developed with Becton Dickinson Electronics’ collaboration 
on the model of ink jet printing technology, which is able to generate droplets and 
change their direction. Its development has benefited from two impetuses of automation. 
The first one was the need of automation to standardize clinical-diagnostic practice. 
The second one came from the NASA research in exobiology (Cambrosio & Keating 
1992a; Keating & Cambrosio 1994). In combination with the production of monoclonal 
antibodies from the hybridoma technology developed by immunologists (Cambrosio 
& Keating 1992b), FACS can sort hematopoietic and leukemic cells according to their 
antigens. Immunologists and hematologists used it for the research of the hematopoietic 
stem cell (see Fagan 2007 for the history of identification and characterization of the 
cells of the hematopoietic hierarchy, including stem cells, by Irving Weissman research 
group). They sorted the cells, transplanted them into lethally irradiated immunodeficient 
mice, and then studied their ability to rescue the hematopoietic system. From these 
studies emerged the first phenotypic characterization of the human hematopoietic 
stem cells: these are CD34+CD38- (Larochelle et al. 1996; see also Weissman et al. 
1989). Identification of the leukemic stem cells followed few months later with the 
same phenotypic characteristics (Bonnet & Dick 1997). This protocol (cell sorting 
and transplantation in immunodeficient mice) rapidly became a gold standard for the 
isolation and characterization of any kind of “adult” or “somatic” stem cells.
Origin of solid cancers in immature cells: The embryonic rests 
theory
     The very idea of the existence of cancer cells that would be stem cells, and that 
would be at the origin of cancers, wasn’t restricted to blood cancers. Indeed, since the 
cell theory from the XIXth century, there have been some proponents of various 
interpretations of embryonic/undifferentiated/stem cells in cancers that are historically 
linked and consistent (even if different in many aspects) with the modern current notion 
of cancer stem cells. Rudolph Virchow, who formulated the second principle of the cell 
theory “omnis cellula e cellula” (the first one being that organism are made of cells; see 
Schwann 1839; Schleiden 1838; Remak 1855; for an historical perspective see 
Duchesneau 1987) also claimed that tumors are developed from the transformation of 
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normal cells (Virchow 1858). But some cases of cancers then appeared struggling 
toexplain, like epithelial cancers located in bones. According to the germ layer theory, 
each cell of the adult organism come from one of the three layers of the embryo 
(endoderm, mesoderm and ectoderm) and no crossing is possible in the fate of the 
cells coming from each layer (Remak 1855). This, in consequence, made impossible 
the development of epithelial cells and epithelial cancroids from bone cells since those 
two kinds of cells come from distinct germ layers (Hannover 1852, see in particular p. 
51 and 21; Lebert 1851). Interestingly, two explanations of occurrences of epithelial 
cancroids in bones were suggested which both involved undifferentiated cells. They are 
often erroneously indistinctly seen as “the embryonal rest theory”.
     The very embryonal rest theory has been suggested by Robert Remak, and hold that 
tumors of that kind (i.e. epithelial cancroids located in tibias, or any other bone of the 
appendix skeleton for that matter) would derived from embryonic cells of their own 
layer, which would have been delocalized during the early development of the embryo 
(Remak 1854, see in particular p. 172). This hypothesis has later been generalized to 
every cancer by Julius Cohnheim (Cohnheim 1875 and 1889, see p. 760 and forward) 
and disseminated (see for examples, Durante 1874; Askanazy 1907; Budde 1926; Willis 
1948).
     The other explanation is quite different. It was developed by Rudolph Virchow and 
his colleague August Foerster, who didn’t put so much emphasize on the germ layer 
theory. They were among those pathologists who had questioned the pertinence of the 
embryological dogma under pathological contexts (see also Klebs 1867; Langhans 
1867). They both argued in favor of an origin of most cancers from cells of the 
connective tissue, which they saw as a “germinal source” (Virchow 1855: 415), a bank 
of undifferentiated cells that provide resources for the emergence of neoplasms and 
neoformations (Virchow 1858, see p. 355; Rather 1978, see p. 131; Fœrster 1855, see 
pp. 180-181 and p. 208).
     The theory of the origin of cancers in undifferentiated cells of the connective tissue 
rapidly felt in desuetude (for an analysis see Rather 1978, p. 154). But the embryonic 
rest theory retained attention during the XX th century in particular for the explanation of 
adamantinomas of the appendix skeleton (the epithelial cancer that had been at the 
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origin of the proposition of the rest theory) and of teratomas and teratocarcinomas. 
Adamantinoma is still a matter of controversy today. The theory of embryonic rests, and 
some modified version of it have been repeatedly suggested to explain their origin 
(Fischer 1913; Richter 1930; Ewing 1940; Schulenburg 1951; Brunner 1936; Lauche 
1947; Rosai 1969; Spjut et al. 1971; Jain et al. 2008). The teratomas and 
teratocarcinomas are tumors that are characterized by the presence of very 
heterogeneous kinds of cells derived from the three germ layers. The historian Andreas-
Holger Maehle reported that numerous experiments were achieved in the early XXth 
century in order to test Cohnheim theory, in particular through tentative of 
transplantation of embryonic cells (for details and references see Maehle 2011). Max 
Askanazy, notably, obtained teratoids by injecting embryonic cells into the abdominal 
cavity of rats, which was according to him a “beautiful” illustration of Cohnheim’s 
theory (Askanazy 1907; Maehle 2011). He was the first to use the concept of “stem 
cells” (Stammzellen) for these residual embryonic cells from which teratocarcinomas 
would originate. Leroy Stevens and collaborators came with the proof of concept that 
teratomas could originate from embryonic cells in the late 60’s by transplanting cells of 
young mice embryos into testis of adult mice and obtaining development of teratomas 
from the transplanted cells (Stevens 1968, 1970; Dunn & Stevens 1970; for a review see 
Damjanov & Solter 1974). Interestingly enough, development of teratomas is now 
considered as a proof of pluripotent embryonic stem cells. In the mean time, Lewis 
Kleinsmith and Gordon Barry Pierce of the Pathology Department of the University of 
Michigan were transplanting the teratocarcinoma cells that look like embryonic cells 
(termed “embryonal carcinoma cells”) to study their potentiality. Pierce and his 
colleagues first demonstrated, against the popular belief, that teratocarcinomas are 
produced by differentiation of multipotential cells (Pierce & Dixon 1959; See also 
Arechaga 1993). He then highlighted the multipotentiality of the cells in which cancers 
originate. He showed that this multipotentiality was restrained to a tiny subpopulation of 
cancer cells, and claimed that "neoplasms consist of a heterogeneous population of cells, 
a small number of which are undifferentiated, highly malignant stem cells; the rest are 
less malignant and more differentiated". (Kleinsmith & Pierce 1964: 1548). Pierce 
himself interpreted his works as a continuity of the embryonal rest theory, often making 
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references to Cohnheim, Askanazy, Budde and Willis. From these first studies, Pierce 
built a general theory of carcinogenesis as a caricature of normal development, 
supported by studies on other cancers, in particular breast and colon cancers (Pierce 
1967; Pierce 1974; Pierce 1977; Pierce et al. 1977).
The cancer stem cell theory at the confluence of these biographies
     A general cancer stem cell theory finally resulted from these biographies, claiming 
three distinct and complementary theses (see in particular Reya et al. 2001 and Clarke et 
al. 2006):
   1) Cancers are hierarchically organized: they are initiated, developed and propagated 
       exclusively by a specific sub-population of cancer cells, the so-called “cancer stem 
       cells” (CSCs).
   2) CSCs explain relapses after apparent healing because (a) they can escape and/or 
       resist to therapies, and (b) they are highly able to initiate a relapse.
   3) Targeting those CSCs is necessary and sufficient to permanently cure cancers.
     These theses raised back hopes to find real cures for cancers. These hopes have been 
taken very seriously, since there has been a profusion and accumulation of data in favor 
of the existence of CSC in various cancers such as leukemias (Bonnet & Dick  1997; 
Cozzio et al. 2003), breast cancers (Al-Hajj et al. 2003), brain tumors (Singh et al. 2003; 
Singh et al. 2004), prostate cancers (Collins et al. 2005; Lawson et al. 2007), ovarian 
cancers (Szotek et al. 2006), liver cancers (Suetsugu et al. 2006; Chiba et al. 2007), 
colorectal cancers (Dalerba et al. 2007; O’Brien et al. 2007; Ricci- Vitiani et al. 2007), 
pancreatic cancers (Li et al. 2007; Hermann et al. 2007), head and neck squamous 
cell carcinomas (Prince et al. 2007), lung cancers (Eramo et al. 2008)... Now a day, 
the development of drugs specifically targeting CSCs raises lots of private and public 
funding. Biotech companies specialized on the R&D of CSC targeting therapeutics are 
blooming since few years, and investments of big pharmas are considerable. IPOs are 
going well, showing a real optimism for the CSC targeting therapeutic strategy. All of 
them seem to shout in unison “off with their head”, convinced that killing CSC might 
solve the cancer problem. But are they right? Or are they like the “blind fury” queen of 
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hearts character in Lewis Carroll’s Alice Adventures in Wonderland?
Ontology matters
     Cancer stem cell became a well-established object around the very beginning of the 
XXIst century. As we have shown, this coming into being followed a century of more or 
less dispersed inquiries and researches, in which CSCs were often studied hand in hand 
with hematopoietic stem cells. But they are not the only stem cells, and their biographies 
are far from subsuming the biographies of others objects also called stem cells, like the 
embryonic stem cells (ES), the induced pluripotent stem cells (iPS) and the totipotent 
stem cells. The multiplicity of stem cells, each with their own biographies, resulted in 
some problems of definitions.
     Indeed, stem cells are classically defined in text-books as those cells that have two 
properties: the capacity to self-renew and the ability to differentiate into two or more 
cell types. This definition is meeting accumulating problems with the profusion of types 
of stem cells. Several biologists had criticized it for being either too inclusive or too 
exclusive. Both criteria appeared too inclusive for the following reasons: (a) some non-
stem cells like lymphocytes can also self-renew (Mikkers & Frisen 2005, Zipori 2004; 
Younes et al 2003), and (b) some non-stem cells like many progenitors (or transit- 
amplifying cells) can also differentiate into two or more different cell types (Lander 
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2009). A possible response to this problem of inclusivity is to consider that stem cells 
possess the two properties whereas (a) progenitors do not self-renew (or not for long 
anyway), and (b) lymphocytes do not differentiate into different cell types (see for 
example Seaberg and van der Kooy 2003). But then, the problem is that together these 
two properties, used to define stem cells, become too exclusive: (1) some stem cells, 
such as mammal embryonic stem cells, do not self-renew in vivo (Lander 2009), indeed 
they belong to transient “emergent tissues” and are part of the organism for a short 
period of time (Shostak 2006) and (2) ‘‘there are unipotent self-renewing cells, most 
notably germ-line stem cells, which most scientists would argue are obvious stem cells’’ 
(Mikkers and Frisen 2005: 2715). One possibility to resolve this problem is to consider 
that germinal stem cells, embryonic stem cells, and all the cells that do not share the two 
properties are not real stem cells. A few scientists follow this path. But it is to be noted 
that they are never working on embryonic or germinal stem cells. This solution does not 
lead to a consensus.
     The stem cell concept has met another crisis during the past decade. The increasing 
needs of stem cells for medical purposes, like regenerative medicine or gene therapies, 
led to a race to the precise phenotypic characterization of the stem cells. It also led 
several groups of biologists to the search of a “stemness signature”. This search relied 
on two major well-implanted presuppositions. The first one was that the two defining 
properties of stem cells (self-renewal and differentiation potency) allow a qualitative 
distinction between stem cells and non-stem cells. This presupposition has met the 
critics we highlighted below. The second one was that these two properties might be 
reducible to molecular characteristics. This presupposition relies on a rather simple idea: 
“Because all SCs share fundamental biological properties, they may share a core set 
of molecular regulatory pathways” (Ivanova et al. 2002, p. 601). This led three major 
groups of the stem cell research community to the search of a genetic characterization 
of stemness. Ihor Lemischka’s group at Princeton compared genetic profile of human 
and mice hematopoietic stem cells and found 283 shared highly expressed genes. They 
thought some of these genes are constitutive of the stemness “genetic program” (Ivanova 
et al. 2002, p. 604). Douglas Melton’s group at Harvard has compared transcription 
profiles of embryonic, neural and hematopoietic mouse stem cells and found a list of 216 
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highly expressed genes (Ramalho-Santos et al. 2002). Finally, Bing Lim’s team from 
the Genome Institute of Singapore, compared gene expression profiling of embryonic, 
neural and retinal stem cells. They found a list of 385 common genes. This last group 
compared their data with the two previous groups and found only one common gene: 
integrin-alpha-6 (ITGA6) (Fortunel et al. 2003). ITGA6 gene codes for the α6 subunit 
of the α6β4 transmembrane protein which is not at all specific to stem cells. Indeed, it 
is primarily found in epithelial differentiated cells (see the Genetics Home Reference of 
NIH).
     These studies have engendered a debate in the scientific community. Several 
interpretations of this failure have been suggested. A popular one consists in imputing 
the failure to the experimental settings (Burns & Zon 2002; Ivanova 2003; Vogel 2003). 
According to this view, scientists should persist so that the “current impressionistic 
portrait of a stem cell may then transform into realism” (Burns & Zon 2002, p. 613). The 
other one, far less popular, consists in considering that “there is no such thing as intrinsic 
stemness at the molecular level, such that perhaps stemness should be understood 
as a relational property between cells and their microenvironment generating the 
functionality of stem cells.” (Robert 2004, p. 1007) This approach has been investigated 
by trying to determine the role of the microenvironment in the fate of stem cells, i.e. 
in the choice between self-renewal and differentiation (see for example Hackney et al. 
2002). The very project of reducing stemness to some genetic characteristics also meets 
another problem. Contrarily to the differentiated cells, the two functional properties 
that define stem cells are rarely actualized because stem cells divide seldom (they are 
often quiescent). Thus, supposing that those two “fundamental biological properties 
[...] share a core set of molecular regulatory pathways” as suggested by Ivanova et al, 
and supposing that those molecular characteristics were identified, those couldn’t be 
sufficient to define or portray stem cells because such a characterization would miss all 
the non-dividing stem cells (i.e. a lot of them). This is a worth-asking question.
     Last but not least, the well implanted idea that differentiation was a one-way street 
going from stem cells to differentiated cells, with no coming back, suffered from various 
challenges, beginning with cloning and increasing lately with iPS cells technologies 
and transdifferentiation (for an historical perspective, see Maienschein 2002). These 
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challenges are often minimized by biologists, arguing that they involve tremendous 
experimental settings. That is to say, these data are restricted to in vitro conclusions. 
They do not challenge the one-way differentiation in vivo. But there are now 
accumulating data challenging this dogma in vivo too. There has been some appealing 
data coming from the regeneration field exhibiting processes of dedifferentiation 
before regeneration (see for example Lo et al. 1993). But those were restricted to few 
species. Since then, it has been proven that in drosophila and mice testis and ovary, 
spermatogonia and cytocytes do dedifferentiate into germline stem cells under certain 
circumstances (Brawley & Matunis, 2004; Kai and Spradling, 2004; Barroca et al. 
2009). Chaffer et al. (2011) have showed that non-stem epithelial cells of the breast 
can spontaneously dedifferentiate to a stem state. They have also highlighted that 
this phenomenon is increased in cancers, where non-stem cancer cells can give rise 
to cancer stem cells in vitro as well as in vivo. The observation of the occurrence of 
epithelial-mesenchymal transitions had been followed by the observation that they 
might cause a de novo acquisition of stemness (Mani et al. 2008). Breast CSCs have 
been generated by this process (Morel et al. 2008). In fact, far from being restricted to 
humans manufacturing experiments, dedifferentiation might be naturally particularly 
efficient in the context of cancers. Indeed, the debate about the origin of CSCs led to the 
demonstration that at least some of the CSC might come from non-stem cells (Passegue 
et al. 2003; Huntly et al. 2004; Krivstov et al. 2006). This means that non-stem cells 
can become stem cells. Other studies have also highlighted the possibility that stemness 
would be an outcome of the cancer process (Rapp et al. 2008; Thirant et al. 2011).
     None of these crises definitely shut down the established stem cell technoscientific 
object. Weissmanian central dogma of stem cell biology considering stem cells as 
stable discrete entities at the head of a non-reversible hierarchy can still be saved. But 
combined, they really put emphasis on the importance of the question “what kind of 
property is stemness?” and on the lack of solid answer to it.
     Some biologists suggested changes in perspectives on that question. Thus, Loeffler 
and Roeder (2002) suggested a revision of the classical definition in which they 
advocated a shift from a “cellular view” to a “system view”. Their aim is “emphasizing 
stemness as a capability rather than as a cellular property” (p. 13). Considering stemness 
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as a capability or a disposition lead to take into consideration the environment, which 
has a major role in the expression or non-expression of the capability. This view has 
been shared by other biologists (French biologists of the USCI personify this position), 
arguing that the role of the microenvironment must be taken into account in our view 
of stem cells, because of the impact it has on the action of stem cells (quiescence, 
asymmetric division, self-renewal symmetric division or differentiation symmetric 
division). Stemness, defined as self-renewal and differentiation, “is not really a property 
that a cell has independent of its environment” argued Lander (2009, p. 70.2) taking 
the example of glucose that can be converted in very distinct substances, depending on 
enzymes, temperature, pH, etc... This led him to the conclusion that stemness might 
even rather be considered as system-level property:
     A similar but not identical view holds that stemness must refer to a (set of) 
function(s) not to an entity. This view is tight with a very original and interesting thesis 
that stemness “can be induced in many distinct types of cells, even differentiated cells” 
(Blau et al 2001: 829; see also Zipori 2004, 2005, 2006, 2009, who is a major advocate 
of this view).
     These new perspectives on stemness have been reframed as the “cell state” hypothesis 
in opposition to an “entity” theory (which is the name given to the orthodoxy) (Fagan 
Forthcoming; Leychkis et al. 2009). We argue that there are rather four (and probably 
more) ontologically distinct views on stemness.
Stemness is a property of systems, rather than cells, with the relevant system being, at 
minimum, a cell lineage, and more likely a lineage plus an environment. A system with 
stemness is typically one that can achieve a controlled size, maintain itself homeostatically, 
and regenerate when necessary (Lander 2009, p. 70.5).
(1) T he orthodoxy (let’s call it “entity ontology”) consists in considering stemness 
as the biological fundamental property of the cells of particular cell types (the 
stem cells).
(2) T he “capability ontology” can be seen as a revision of the entity theory. It can 
still support the idea that stemness is a distinctive property of stem cells. But 
the property itself is view as a “disposition” or “capability”, which might not be 
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     All these propositions of reevaluation of our ontological understanding of “stem cell” 
share the idea that the concept of “stem cell” does not refer to an entity like “neuron” or 
“erythrocyte” does. Question remains to determine if it refers to a capability, a cell or a 
system?
Cutting heads might be endless
     We would like to highlight the practical consequences of those distinct ontological 
perspectives on stemness.
     First let’s remember that the coming into being and stabilization of cancer stem 
cells preceded the appearance of those debates. Thus, the cancer stem cell theory, 
and more precisely, the model of anti-CSC therapeutic strategy, is based on the entity 
ontology of stemness. Indeed, the idea that the destruction of the CSCs might led to the 
definitive elimination of a cancer rely on two presuppositions: first, CSC are somehow 
qualitatively distinct and distinguishable from other cancer cells; second, stemness is a 
stable property and differentiation is a one-way street.
     What might be the consequences of any change in ontological perspective on 
stemness?
      expressed unless the right conditions are met. The consequence is an integration 
      of the microenvironment in the consideration of the property itself. One cannot
      study stemness without studying the extracellular factors involved in its 
      expression and regulation.
(3) T he “system ontology” abandons the very idea of stem cells and just retains the 
stemness, which is ascribed to a “system” rather than to a cell, that is a lineage 
plus its environment.
(4) T he “state ontology” considers the stemness as a cell property, but as the property 
of any cell (or almost any cell). This might also be called “relational ontology” 
as has been suggested by Robert (2004, p. 1007) because it is the relation that a 
cell has with other cells or with a microenvironment that determines its stem or 
non-stem state.
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What if stemness was a disposition/capability?
     If stemness is a capability, then CSCs can be distinguished from non-CSCs and 
specifically targeted in order to cure cancer. If succeeded, the outcome would predictably 
be the same than if stem cells were classical entities: without CSC, cancers that respond 
to the CSC model won’t be able to maintain themselves and will regress and disappear. 
This would ultimately lead to an effective cure.
     This ontological perspective on stemness, however, put emphasis on the comportment 
of stem cells. This have a particular consequence for elimination of the CSC: any CSCs 
targeting therapy that would focus on the stemness properties of CSCs might encounter 
the reductionist problem we have highlighted about the seeking for a genetic portrait 
of stemness. Indeed, the targeting of CSCs through a functional signature could miss 
the quiescent CSCs. As far as genetic signatures are concerned, there might be two 
populations of CSCs rather than one: a population of active CSCs and a population 
of quiescent CSCs, each presenting a deferent signature. This heterogeneity shoud be 
taken into account in the design of new drugs. Only the elimination of all the CSC could 
achieve the goal of an effective and definitive cure.
     The dispositional view also suggests another plausible therapeutic strategy. Indeed, 
if stemness is a disposition, then cancer stem cells activities rely on the conditions 
of expression of stemness. Thus, destroying these conditions should lead to the 
maintenance of the CSC out of the stem state. This should, in turn, lead to the same 
result than the elimination of the CSC, i.e. disappearance of the cancer cells population, 
which would no longer be fed by the CSC.
What if stemness was a system property?
     If stemness is a system property, then cell targeting appears misled since there are no 
cells to be targeted. This ontological perspective, however, has to be clarified. At current 
state, the factors involved in the expression of stemness by a system are not clear. What 
does it mean to be a system property and what would it take to prevent a system like a 
cancer to express stemness? Furthermore, the difference between the system ontology 
and the state ontology has to be strengthened. Indeed, one possible interpretation of the 
system ontology would be that stemness is expressed by some cells but under the control 
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of the whole system. Let’s take a metaphor in order to give an example: in a soccer team, 
a player may be replaced by another without affecting the tactical scheme. For example, 
since her retirement the ex-international French feminine player Stéphanie Mugneret-
Béghé has been replaced like-for-like by Gaëtane Thiney. The midfielder position 
and function has been preserved despite the loss of the former player. This metaphor 
illustrates that in a given system, a function can be attributed to a substitutable item. 
In this case the loss of the item doesn’t affect the system-level function as long as new 
items can replace the former one. This means that CSC targeting therapies cannot be 
effective and will lead to relapses through induction of stemness among cancer cells. By 
contrast, the therapeutic strategy of eliminating the conditions of expression of stemness 
previously suggested could prove successful.
What if stemness was a relational property?
     If stemness is a relational property then targeting CSCs might be endless as cancerous 
non-stem cells could acquire stemness at anytime if the right relation conditions are met. 
In this case, a CSCs targeting therapies would either never end or likely lead to relapse.
     This relational ontology is akin to the second interpretation of the system ontology. 
Nevertheless, we would like to extend the soccer metaphor to highlight a difference. The 
relational ontology focuses on an item plus its relations whereas the system ontology 
focuses on the functions at the system level. In soccer, a player substitution is a good 
example of the system ontology; a player who endorses a new field position would be 
an example of the relational ontology. The relational ontology highlights the possibility 
for an item to acquire a new function. For example, last year, in her new team (ES 16), 
Stéphanie Mugneret-Béghé has played sweeper or defensive midfielder, depending on 
several types of “relations” imposing her one or the other of these functions (coaches, 
team needs, other players’ availability and conditions, etc.). The change in focus from 
the system to the item is far from irrelevant. For example Stéphanie Mugneret-Béghé 
could probably play every position, but she would be far better as midfielder than as 
goalkeeper for at least historical reasons: she never trained as a goalkeeper! Biographies 
of the cells might also have consequences in their ability to express stemness. For 
example, a red blood cell could never revert to a stem state because they don’t have 
Lucie Laplane 91
nucleus anymore. It seems highly probable that cells are unequal in their ability to be 
dedifferentiated, depending on their morphology, chromatin state and other criteria. 
From this it follows that a therapeutic strategy based on induction of differentiation 
might be successful if the differentiation were adequate, at least in certain types of 
cancers.
Conclusion
     In this chapter, we have tried to show that ontologies of technoscientific objects 
can be history-laden. The coming into being of cancer stem cell is an example of 
technoscientific object whose ontology is tightly committed to its selective biographies. 
We claim that those biographies-laden ontologies can have critical practical 
consequences. The case of cancer stem cells is paradigmatic. Through their biographical 
narratives, we have highlighted the “entity” ontology of the CSC. A broader view on 
stemness shows that the “entity” ontology is in fact competed by other ontological 
views, for whom supports are recently growing. We have emphasized that these other 
ontologies cast important doubts on the feasibility and usefulness of the CSC targeting 
strategy supported by the classical ontology, that raise so many hopes, funding and 
efforts. They also highlight other plausible therapeutic strategies that might also deserve 
researches, attentions and funding.
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